论文部分内容阅读
目的探讨血液透析滤过治疗尿毒症顽固性高血压的临床疗效。方法本文对收治的尿毒症顽固性高血压患者采用血液透析滤过治疗,并与进行血液透析治疗的HD组进行临床效果比较。结果 HDF组显效16例,有效14例,总有效率达96.77%;HD组显效10例,有效13例,总有效率达74.19%;经统计学分析发现HDF组的显效率和总有效率明显高于HD组,且差异具有统计学意义(P<0.05)。治疗4周后,HD组和HDF组患者收缩压、舒张压及血浆RA、AngⅡ浓度均明显下降,与治疗前比较差异有统计学意义(P<0.05),HDF组治疗后的上述各项指标与HD组治疗后比较下降更显著(P<0.05)。结论血液透析滤过可以显著降低尿毒症顽固性高血压患者的收缩压和舒张压,可使血浆RA、AngⅡ浓度明显下降,从而使顽固性高血压得到控制,且减少心脑血管并发症的发生,值得临床推广应用。
Objective To investigate the clinical efficacy of hemodiafiltration in treating refractory hypertension of uremia. Methods The treatment of refractory hypertensive patients with uremia hemodialysis filtration treatment, and with the hemodialysis HD group for clinical effect comparison. Results In HDF group, 16 cases were markedly effective and 14 cases were effective. The total effective rate was 96.77%. In HD group, 10 cases were markedly effective and 13 cases were effective. The total effective rate was 74.19%. Obvious efficiency and total effective rate were found in HDF group Higher than HD group, and the difference was statistically significant (P <0.05). After 4 weeks of treatment, the systolic blood pressure, diastolic blood pressure and plasma RA, Ang Ⅱ concentrations in HD group and HDF group were significantly decreased (P <0.05), and the above indexes Compared with the HD group after treatment more significant decline (P <0.05). Conclusion Hemodiafiltration can significantly reduce the systolic and diastolic blood pressure in uremic patients with refractory hypertension, can significantly reduce the plasma RA, Ang Ⅱ concentration, so that stubborn hypertension can be controlled and reduce the occurrence of cardiovascular and cerebrovascular complications ,Worthy of clinical application.